Čájehuvvojit 1 - 7 oktiibuot 7 bohtosis ohcui Hussain Elhasasna (14851130)', ohcanáigi: 0,01s Aiddostahte ozu
  1. 1
    Supplementary Table S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Dahkki Amr El Zawily (14851115)

    Almmustuhtton 2025
    Eará dahkkit:
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    Supplementary Table S7 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S7 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Dahkki Amr El Zawily (14851115)

    Almmustuhtton 2025
    Eará dahkkit:
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    Supplementary Table S5 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S5 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Dahkki Amr El Zawily (14851115)

    Almmustuhtton 2025
    Eará dahkkit:
    Lasit oiddohiidda
    Furkejuvvon:
  4. 4
    Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Dahkki Amr El Zawily (14851115)

    Almmustuhtton 2025
    Eará dahkkit:
    Lasit oiddohiidda
    Furkejuvvon:
  5. 5
    Supplementary Table S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Dahkki Amr El Zawily (14851115)

    Almmustuhtton 2025
    Eará dahkkit:
    Lasit oiddohiidda
    Furkejuvvon:
  6. 6
    Supplementary Table S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Dahkki Amr El Zawily (14851115)

    Almmustuhtton 2025
    Eará dahkkit:
    Lasit oiddohiidda
    Furkejuvvon:
  7. 7
    Supplementary Table S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Dahkki Amr El Zawily (14851115)

    Almmustuhtton 2025
    Eará dahkkit:
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: